NT 814

Drug Profile

NT 814

Latest Information Update: 17 Aug 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer NeRRe Therapeutics
  • Class
  • Mechanism of Action Neurokinin 1 receptor antagonists; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Opioid abuse; Sex hormone disorders
  • Phase I/II Vasomotor symptoms

Most Recent Events

  • 01 Aug 2016 Phase-I/II clinical trials in Vasomotor symptoms in USA (PO) (NCT02865538)
  • 15 Mar 2016 Phase-II clinical trials in Opioid abuse in United Kingdom (PO) before March 2016
  • 15 Mar 2016 Phase-II clinical trials in Sex hormone disorders in United Kingdom (PO) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top